Wyniki wyszukiwania - Biblioteka Nauki

1

Arginine methylation analysis of the splicing-associated SR protein SFRS9-SRP30C

100%

Bressan G. C. , Moraes E. C. , Monfiolli A. O. , Kuniyoshi T. M. , Passos D. O. , Gomes M. D. , Kobarg J.

Cellular and Molecular Biology Letters

|

2009

|

tom 14

|

nr 4

657-669

EN

The human SFRS9/SRp30c belongs to the SR family of splicing regulators. Despite evidence that members of this protein family may be targeted by arginine methylation, this has yet to be experimentally addressed. In this study, we found that SFRS9 is a target for PRMT1-mediated arginine methylation in vitro, and that it is immunoprecipitated from HEK-293 lysates by antibodies that recognize both mono- and dimethylated arginines. We further observed that upon treatment with the methylation inhibitor Adox, the fluorescent EGFP-SFRS9 re-localizes to dot-like structures in the cell nucleus. In subsequent confocal analyses, we found that EGFP-SFRS9 localizes to nucleoli in Adox-treated cells. Our findings indicate the importance of arginine methylation for the subnuclear localization of SFRS9.

2

MRI as a potential tool for monitoring of therapeutic monoclonal antibody distribution in cancer patients

100%

Tabarkiewicz J. , Aebisher D. , Bartusik-Aebisher D.

Acta Poloniae Pharmaceutica - Drug Research

|

2020

|

tom 77

|

nr 3

383-389

EN

Imaging and quantification of MAbs distribution by MRI after administration in vivo can improve patient outcomes, although it is not routinely used in the clinic hence the motivation for development of new MAbs imaging methodologies. Improvements in imaging and quantification of antibody distributions can be made by conjugating MAbs to “hotspot” atoms such as 19F as 19F Currently, research investigating the incorporation of 19F to antibody delivery systems has been limited to trastuzumab perfluorocarbon emulsions and this method has not been extended to other clinically approved antibodies. The methodologies of 19F MRI can improve current limitations of antibody immunotherapy such as quantitative visualization of targeted surface antigens expressed on tumor cells.

3

Antigen detected on normal human B lymphocytes by BR31 monoclonal antibody - the nature of the antigen and its functional properties

88%

Skibinski G. , Wieczorek Z.

Archivum Immunologiae et Therapiae Experimentalis

|

1989

|

tom 37

|

nr 3-4

4

Potential role of HSP proteins in snails of the genus Helix

88%

Nowakowska A. , Rogalska J. , Caputa M.

Folia Malacologica

|

2016

|

tom 24

|

nr 1

5

Characterization of mAb6-9-1 monoclonal antibody against hemagglutinin of avian influenza virus H5N1 and its engineered derivative, single-chain variable fragment antibody

88%

Sawicka R. , Siedlecki P. , Kalenik B. , Radomski J. , Sączyńska V. , Porębska A. , Szewczyk B. , Sirko A. , Góra-Sochacka A.

Acta Biochimica Polonica

|

2017

|

tom 64

|

nr 1

85-92

EN

Hemagglutinin (HA), as a major surface antigen of influenza virus, is widely used as a target for production of neutralizing antibodies. Monoclonal antibody, mAb6-9-1, directed against HA of highly pathogenic avian influenza virus A/swan/Poland/305-135V08/2006(H5N1) was purified from mouse hybridoma cells culture and characterized. The antigenic specificity of mAb6-9-1 was verified by testing its cross-reactivity with several variants of HA. The mimotopes recognized by mAb6-9-1 were selected from two types of phage display peptide libraries. The comparative structural model of the HA variant used for antibody generation was developed to further facilitate epitope mapping. Based on the sequences of the affinity- selected polypeptides and the structural model of HA the epitope was located to the region near the receptor binding site (RBS). Such localization of the epitope recognized by mAb6-9-1 is in concordance with its moderate hemagglutination inhibiting activity and its antigenic specificity. Additionally, total RNA isolated from the hybridoma cell line secreting mAb6-9-1 was used for obtaining two variants of cDNA encoding recombinant single-chain variable fragment (scFv) antibody. To ensure high production level and solubility in bacterial expression system, the scFv fragments were produced as chimeric proteins in fusion with thioredoxin or displayed on a phage surface after cloning into the phagemid vector. Specificity and affinity of the recombinant soluble and phage-bound scFv were assayed by suitable variants of ELISA test. The observed differences in specificity were discussed.

6

IgG subclasses distribution in immunoglobulin preparations for intravenous use

88%

Bozadjiev L. G. , Bineva I. L. , Vassilev T. L.

Archivum Immunologiae et Therapiae Experimentalis

|

1992

|

tom 40

|

nr 1

7

Synthesis and macromolecular organization of gastrointestinal mucin

88%

Slomiany A. , Slomiany B. L.

Journal of Physiology and Pharmacology

|

1992

|

tom 43

|

nr 2

EN

Mucus glycoproteins (mucins), the principal determinants of mucus protective qualities and mucosal defense, are studied extensively to define pathological aberrations in the relation to gastrointestinal disease and to develop the mucous barrier strengthening agents. Recent work from our laboratory provided evidence as to the initial stages of the gastrointestinal mucin synthesis, molecular size of the apomucin, its macromolecular organization and interaction with other elements of gastrointestinal mucus. Using monoclonal antibodies against apomucin (clone 1H7), O- glycosylated with N-acetylgalactosamine apomucin (clone 2B4), and that against carboxyl terminal of the apomucin (clone 3G12), the mucin synthesizing polysomes were isolated and glycosylated peptides ranging in size from 6-60kDa identified. The in vitro synthesis in the cell-free system also afforded 60-64kDa products recognized by 1H7 and 3G12 antimucin MAbs. The obtained results provided evidence that the mucin core consists of 60kDa peptide which at cotranslational stage is O-glycosylated with N-acetylgalactosamine. Studies on mucin polymer assembly revealed that mucin preparations prepared by equilibrium density gradient centrifugation and Sepharose 2B chromatography (Mantle, M., Mantle, D., and Allen, A. (1981) Biochem. J. 195, 277-285) are not completely purified and contain DNA and extraneous proteins. The evidence was obtained that so called mucin “link protein”, 118kDa glycopeptide, is a N-glycosylated fragment of fibronectin, whereas the supposedly native undegraded mucin isolated by Carlstedt et al. (Biochem. J. (1983) 211, 13-22) was found to contain mucin-fibronectin-DNA complexes. The general picture that emerged from the studies is that the pure mucin consists of 60kDa glycosylated peptides only. The carboxyl terminal (8-12kDa fragment) of these peptides is not glycosylated (naked) and is responsible for mucin interaction with fibronectin and other fibronectin-like extracellular matrix proteins. While the formation of the mucosal coat depends on many other factors and extracellular components, our findings on mucin structure and interaction with the extracellular matrix proteins provide explanation as to the possible mechanism of mucin adherence to the epithelial surfaces.

8

CD30 expression on allergen- and non-allergen-specific T cell lines and its role in cytokine production

88%

Tarkowski M.

Archivum Immunologiae et Therapiae Experimentalis

|

2003

|

tom 51

|

nr 5

9

Detection of CMV infected cells by flow cytometry - evaluation of MAbs CCH2 and AAC10 directed against early and late CMV antigens

88%

Siennicka J.

Polish Journal of Microbiology

|

2004

|

tom 53

|

nr 2

EN

In this work evaluation of usefulness of monoclonal antibodies (MAbs) CCH2 and AAC10 directed against early - pUL44(DB52) and late - ppUL83(pp65) CMV antigens, utilized in Department of Virology, NIH for routine diagnosis of CMV infection by shell vial and pp65 antigenemia assay, for determination of CMV antigens by flow cytometry in human leucocytes, isolated, infected and cultivated in vitro was presented.

10

Characterization of immunoreactive proteins of Setaria cervi isolated by preparative polyacrylamide gel electrophoresis

75%

Priyadarshi P. , Dravid P. , Sheikh I. H. , Saxena S. , Tandon A. , Kaushal D. C. , Ali S. , Kaushal N. A.

Acta Parasitologica

|

2017

|

tom 62

|

nr 1

11

T lymphocyte subpopulations in patients with chronic active hepatitis B virus infection characterized by monoclonal antibodies

75%

Dworniak D. , Tchorzewski H. , Pokoca L. , Tkacz B. , Drobnik S. , Baj Z.

Archivum Immunologiae et Therapiae Experimentalis

|

1989

|

tom 37

|

nr 3-4

12

Different pattern of haemagglutinin immunoreactivity of equine influenza virus strains isolated in Poland

75%

Kwasnik M. , Gora I. M. , Rozek W.

Bulletin of the Veterinary Institute in Puławy

|

2015

|

tom 59

|

nr 4

EN

The immunoreactivity of haemagglutinin (HA) polypeptides of equine influenza virus was compared among the strains isolated in Poland, using H3 monoclonal antibody. A stronger signal in immunoblot reaction was observed for A/equi/Pulawy/2008 HA polypeptides compared to A/equi/Pulawy/2006, despite the fact that both strains are phylogenetically closely related and belong to Florida clade 2 of American lineage. The strongest signal, observed in the case of A/equi/Pulawy/2008, seemed to be connected with the presence of G135, 1213, E379, and/or V530 instead of R135, M213, G379, and 1530 present in A/equi/Pulawy/2006 HA sequence. This implies that point mutations within amino acid sequences of HA polypeptides of equine influenza virus may change their immunoreactivity even when they are not located within five basic antigenic sites.

13

Effect of a monoclonal antibody against cytochrome P-450 on the metabolism of benzo(a)pyrene in C57B1/10 mouse liver microsomes

75%

Brauze D. , Mikstacka R.

Bulletin of the Polish Academy of Sciences. Biological Sciences

|

1989

|

tom 37

|

nr 10-12

14

Nanoantibodies: small molecules, big possibilities

75%

Pedreanez A. , Mosquera-Sulbaran J. , Munoz N. , Tene D. , Robalino J.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2021

|

tom 102

|

nr 3

15

Validation of a flow cytometry-based assay for monitoring complement-dependent cytotoxicity of an anti-CD20 biosimilar candidate antibody

75%

Blanco-Santana R. , Cedeno-Arias M. , Garcia-Perez Z. , Columbie-Gilbert D. , Portillo-Vaquer A. , Rengifo-Calzado E.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2014

|

tom 95

|

nr 1

16

Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression

75%

Bzowska M. , Mezyk-Kopec R. , Prochnicki T. , Kulesza M. , Klaus T. , Bereta J.

Acta Biochimica Polonica

|

2013

|

tom 60

|

nr 3

EN

Blood and lymphatic vessel formation is an indispensable factor for cancer progression and metastasis. Therefore, various strategies designed to block angiogenesis and lymphangiogenesis are being investigated in the hope to arrest and reverse tumor development. Monoclonal antibodies, owing to their unequalled diversity and specificity, might be applied to selectively inhibit the pathways that cancer cells utilize to build up a network of blood vessels and lymphatics. Among the possible targets of antibody-based therapies are proangiogenic and prolymphangiogenic growth factors from the VEGF family and the receptors to which they bind (VEGFRs). Here, we present molecular mechanisms of angiogenesis and lymphangiogenesis exploited by tumors to progress and metastasise, with examples of antibody-based therapeutic agents directed at interfering with these processes. The expanding knowledge of vascular biology helps to explain some of the problems encountered in such therapies, that arise due to the redundancy in signaling networks controlling the formation of blood and lymphatic vessels, and lead to tumor drug resistance. Nonetheless, combined treatments and treatments focused on newly discovered proangiogenic and prolymphangiogenic factors give hope that more prominent therapeutic effects might be achieved in the future.

17

Cross-reaction of 791T/36 monoclonal antibody with immunological activated human peripheral blood mononuclear cells

75%

Rytwinski K.

Archivum Immunologiae et Therapiae Experimentalis

|

1988

|

tom 36

|

nr 6

18

Evaluation of Wondfo Rapid Diagnostic Kit (Pf-HRP2/PAN-pLDH) for diagnosis of malaria by using nano-gold Immunochromatographic assay

75%

Wu J. , Peng Y. , Liu X. , Li W. , Tang S.

Acta Parasitologica

|

2014

|

tom 59

|

nr 2

EN

Prompt and accurate diagnosis is necessary to start adequate treatment for different affecting species including P. falciparum and P. vivax. Here we described the Wondfo Rapid diagnostic Kit (Pf-HRP2/PAN-pLDH) for the detection of P. falciparum and pan-plasmodium in patient specimen by using a nano-gold immunochromatographic assay. Our rapid assay adapted nano-gold labeling techniques and the monoclonal antibodies (mAbs) against both histidine rich protein-2 (Pf HRP-2) of P. falciparum and pan plasmodium-specific pLDH (pan pLDH). The established two-antibody sandwich immunochromatographic assay could detect P. falciparum and pan-plasmodium. The sensitivity and specificity of Wondfo rapid diagnostic kit were determined by comparing with the “gold standard” of microscopic examination of blood smears. In this study1023 blood samples were collected from outpatient clinics in China and Burma, and detected by both Wondfo kit and microscopic examination. The detection sensitivity and specificity of Wondfo rapid diagnostic kit were 96.46% and 99.67% for P. falciparum (HRP2), 95.03% and 99.24% for pLDH, 96.83% and 99.74% for non-falciparum species, 96.70% and 99.74% for P. vivax, respectively. These results indicate that Wondfo rapid diagnostic assay may be useful for detecting P. falciparum and non-P. falciparum (especially P.v.) in patient specimen.

19

Quantification of the CD8plus T cell response against a mucin epitope in patients with breast cancer

75%

Kokowski K. , Harnack U. , Dorn D. C. , Pecher G.

Archivum Immunologiae et Therapiae Experimentalis

|

2008

|

tom 56

|

nr 2

20

Monoclonal antibodies recognizing bovine leukocyte antigens used in immuno-scanning electron microscopy

75%

Levkut M. , Ponti W. , Levkutova M. , Quirici N.

Folia Histochemica et Cytobiologica

|

1995

|

tom 33

|

nr 3